FDA will consider expanded use of Astellas' cancer drug erlotinib

01/18/2013 | Pharmaceutical Business Review Online

Astellas Pharma said the FDA has accepted its supplemental new drug application for Tarceva, or erlotinib, as a first-line treatment for EGFR-positive metastatic or locally advanced nonsmall-cell lung cancer. The application was given priority-review designation.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA